Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-552-2 | CAS number: 108-12-3
Endpoint summary
Administrative data
Description of key information
No data is available for isovaleryl chloride. However, the toxicological profile of the non-branched isomer valeryl chloride and isovaleryl chloride are very similar. Due to their reactivity both acid chlorides react locally with human tissue at the port of entry and/or hydrolyze to form hydrochloric acid and valeric acid or isovaleric acid. Both compounds show high corrosivity (Cat 1A) which explains at least in part their acute toxic effects. There is an acute inhalation toxicity study available which can be used for the assessment of the acute inhalative toxicity potential of isovaleryl chloride.
The LC50 for valeryl chloride in rats was found to be 2.07 mg/L.
Key value for chemical safety assessment
Acute toxicity: via dermal route
Endpoint conclusion
- Value:
- mg/kg bw
Additional information
Inhalation toxicity
No data is available for isovaleryl chloride. However, study results for the the isomer valeryl chloride is available which can be used for the assessment of isovalerylchloride.
In a GLP compliant OECD 403 guideline study in which rats (5/sex/group) were exposed for 4 hours to 0.35, 2.02 and 4.86 mg/L valeryl chloride, no deaths were observed after a 14-day observation period at the lowest exposure level, 3/5 males and 2/5 females died at the medium exposure level and 4/5 males and 5/5 females at the highest exposure level after 14 days (BASF AG, 1990). The LC50 value was calculated to be 2.07 mg/L. General congestion in all animals, focal hyperemia with emphysema in the lungs (2.02 mg/L) and focal hyperemia with emphysema and edema in the lungs (4.86 mg/L) were observed in the animals that died during the study. Clinical signs included irregular and accelerated respiration, eyelid closure, eye discharge, restlessness and ruffled fur at all exposure levels; additionally: intermittent respiration, salivation, nasal discharge, nose with smear and crusts, stretched position when breathing, squatting posture and deteriorated general state at the mid and high concentration.
Oral and dermal toxicity
Further studies regarding acute oral and dermal toxicity do not have to be performed: in accordance with column 2 of REACH Annex VIII as the substance is classified as corrosive to the skin according to Directive 67/548/EEC (C, R35) and according to the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008 (H314, Category 1A).Justification for classification or non-classification
The available acute inhalation toxicity data warrants classification with Xn; R20 according to Directive 67/548/EEC and Cat. 3; H331 according to the EU Classification, Labelling and Packaging of Substances and Mixtures (CLP) Regulation (EC) No. 1272/2008.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
